Arvinas Inc.
5 Science Park
395 Winchester Ave
New Haven
Connecticut
06511
United States
Website: https://www.arvinas.com/
About Arvinas Inc.
At Arvinas, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a clinical-stage biopharmaceutical company focused on developing new therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Our leading programs are focused on high-value targets in cancer, including the androgen and estrogen receptors associated with prostate and breast cancers, respectively. Our hope is to unlock the full potential of PROTAC protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.
QUALITY BENEFITS
Designed with health and wellness in mind, employees and their families are eligible for:
- Medical, dental, and vision options, including a generous company contribution into an HSA
- Paid maternity and paternity leave
- FSA, HSA, Healthcare, and Dependent Care accounts
- Company provided life insurance and short/long-term disability coverage
- Additional voluntary benefits including critical illness, hospital care and more
COMPENSATION & EQUITY
Central to our organization is attracting, retaining and engaging the best and brightest by sharing in the success of our organization:
- Competitive salaries and an annual incentive program
- 401K matching program with immediate vesting
- Eligibility for long-term equity incentives upon hire and annually
TIME OFF
We believe it’s important to relax, unwind and enjoy life’s moments:
- Paid vacation
- A year-end office closure
- Observed company holidays
- Paid sabbatical upon 5 years’ tenure
We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. We take our work very seriously, but we also ensure we’re having fun while doing it. We embrace the freedom to pursue innovation, think creatively, and give back. We care about each other, celebrate our accomplishments, and rise up to encourage our colleagues through challenges. If you think one of these open positions might be a fit, we’d love to hear from you.
Working at Arvinas
136 articles about Arvinas Inc.
-
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
-
Novartis on Thursday announced that it is making $150 million in upfront payments to protein degradation biotech Arvinas, while separately revealing that its tender offer for MorphoSys has begun.
-
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
4/11/2024
Arvinas, Inc. announced it has entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor degrader for patients with prostate cancer.
-
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
3/18/2024
Arvinas, Inc. announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of Chief Medical Officer and a member of the Executive Committee reporting to President and Chief Executive Officer John Houston, Ph.D. Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.
-
Arvinas to Participate in Upcoming March 2024 Investor Conferences
3/4/2024
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that management will participate in three upcoming investor conferences.
-
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2/27/2024
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
2/20/2024
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first subject was dosed in its Phase 1 clinical trial of ARV-102, the Company’s first oral PROTAC® (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases.
-
Arvinas Announces Chief Financial Officer Transition
2/20/2024
Arvinas, Inc. announced that after more than a decade with the company, Sean Cassidy, C.P.A, Chief Financial Officer and Treasurer, will be leaving the company to pursue a new opportunity, effective February 29, 2024.
-
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
2/6/2024
Arvinas, Inc. and Pfizer Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of vepdegestrant for monotherapy in the treatment of adults with estrogen receptor positive/human growth epidermal growth factor 2 negative locally advanced or metastatic breast cancer previously treated with endocrine-based therapy.
-
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
2/1/2024
Arvinas, Inc. (Nasdaq: ARVN) today announced that Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development will participate in a fireside chat at the 6th Annual Guggenheim Biotechnology Conference on Wednesday, February 7 at 10:30 a.m. ET in New York.
-
Arvinas Appoints Jared Freedberg as General Counsel
1/16/2024
Arvinas, Inc. announced that Jared Freedberg, J.D., has joined the company as General Counsel.
-
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
12/6/2023
Arvinas, Inc. announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc. to discuss vepdegestrant data presented at the 2023 San Antonio Breast Cancer Symposium as well as plans to expand the vepdegestrant development program.
-
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
12/5/2023
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced clinical data for vepdegestrant (ARV-471), a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib (IBRANCE®).
-
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
11/28/2023
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).
-
Arvinas Announces Oversubscribed $350 Million Private Placement
11/27/2023
Arvinas, Inc. today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 12,963,542 shares of common stock at a price of $21.36 per share.
-
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/7/2023
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
-
Arvinas to Participate in Upcoming November 2023 Investor Conferences
11/2/2023
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that management will participate in five upcoming investor conferences.
-
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
10/22/2023
Arvinas, Inc. announced the presentation of interim data from the Company’s Phase 1/2 clinical trial for bavdegalutamide, a novel PROTAC® protein degrader targeting the androgen receptor, in a poster session at the European Society for Medical Oncology Congress being held in Madrid from October 20 – 24, 2023.
-
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
10/15/2023
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced it will present updated Phase 1/2 trial data for bavdegalutamide at the 2023 European Society for Medical Oncology Annual Congress.
-
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
10/15/2023
Arvinas, Inc. and Pfizer Inc. announced they will present updated Phase 1/2 data for vepdegestrant at the 2023 European Society for Medical Oncology Annual Congress.